139 related articles for article (PubMed ID: 21843660)
1. Hematologic toxicities associated with intravenous immunoglobulin therapy.
Baxley A; Akhtari M
Int Immunopharmacol; 2011 Nov; 11(11):1663-7. PubMed ID: 21843660
[TBL] [Abstract][Full Text] [Related]
2. Role of intravenous immunoglobulin G in autoimmune hematologic disorders.
Blanchette VS; Kirby MA; Turner C
Semin Hematol; 1992 Jul; 29(3 Suppl 2):72-82. PubMed ID: 1509297
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
[TBL] [Abstract][Full Text] [Related]
4. Guidelines on the use of intravenous immune globulin for hematologic conditions.
Anderson D; Ali K; Blanchette V; Brouwers M; Couban S; Radmoor P; Huebsch L; Hume H; McLeod A; Meyer R; Moltzan C; Nahirniak S; Nantel S; Pineo G; Rock G
Transfus Med Rev; 2007 Apr; 21(2 Suppl 1):S9-56. PubMed ID: 17397769
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies.
Bayry J; Fournier EM; Maddur MS; Vani J; Wootla B; Sibéril S; Dimitrov JD; Lacroix-Desmazes S; Berdah M; Crabol Y; Oksenhendler E; Lévy Y; Mouthon L; Sautès-Fridman C; Hermine O; Kaveri SV
J Autoimmun; 2011 Feb; 36(1):9-15. PubMed ID: 20970960
[TBL] [Abstract][Full Text] [Related]
6. [Administration of intravenous immunoglobulins in adult patients with hematologic diseases].
Antunović P
Srp Arh Celok Lek; 1993; 121(8-12):155-7. PubMed ID: 7725161
[TBL] [Abstract][Full Text] [Related]
7. [Use of intravenous immunoglobulin in treatment of neoplasms and hematologic disorders in children].
Wróbel G; Chybicka A; Kazanowska B
Postepy Hig Med Dosw; 2002; 56 Suppl():59-68. PubMed ID: 12661416
[TBL] [Abstract][Full Text] [Related]
8. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
9. Use of intravenous immunoglobulin G (IVIG).
Looney RJ; Huggins J
Best Pract Res Clin Haematol; 2006; 19(1):3-25. PubMed ID: 16377538
[TBL] [Abstract][Full Text] [Related]
10. [Use of high-dose intravenous immunoglobulins in pediatric hematology].
Massolo F; Flori C; Cellini M; Baraldi C; Iori G
Pediatr Med Chir; 1994; 16(1):37-41. PubMed ID: 8029087
[TBL] [Abstract][Full Text] [Related]
11. Safety of intravenous immunoglobulin (IVIG) therapy.
Katz U; Achiron A; Sherer Y; Shoenfeld Y
Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
[TBL] [Abstract][Full Text] [Related]
12. [Intravenous immunoglobulin in multiple sclerosis].
Ota K
Nihon Rinsho; 2003 Aug; 61(8):1374-80. PubMed ID: 12962026
[TBL] [Abstract][Full Text] [Related]
13. [The use of intravenous immunoglobulins in the treatment of primary immunodeficiencies].
Lewandowicz-Uszyńska A; Jankowski A
Pol Merkur Lekarski; 2011 Jun; 30(180):409-12. PubMed ID: 21751549
[TBL] [Abstract][Full Text] [Related]
14. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy.
Gerstenblith MR; Antony AK; Junkins-Hopkins JM; Abuav R
J Am Acad Dermatol; 2012 Feb; 66(2):312-6. PubMed ID: 21601310
[TBL] [Abstract][Full Text] [Related]
15. [Intravenous immunoglobulin therapy].
Mouthon L
Rev Prat; 2005 May; 55(10):1049-56. PubMed ID: 16097244
[TBL] [Abstract][Full Text] [Related]
16. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders.
Emmi L; Chiarini F
Neurol Sci; 2002 Apr; 23 Suppl 1():S1-8. PubMed ID: 12032582
[TBL] [Abstract][Full Text] [Related]
17. [Intravenous immunoglobulin therapy for kidney diseases in children].
Zwolińska D
Pol Merkur Lekarski; 2011 Jun; 30(180):423-6. PubMed ID: 21751552
[TBL] [Abstract][Full Text] [Related]
18. High-dose intravenous immunoglobulin in the management of immune hemolysis in patients with thalassemic disease: factors which determine refractoriness.
Wanachiwanawin W; Pootrakul P; Fucharoen S; Piankijagum A
Southeast Asian J Trop Med Public Health; 1991 Sep; 22(3):397-401. PubMed ID: 1726338
[TBL] [Abstract][Full Text] [Related]
19. [Use of high dose intravenous immunoglobulin in neurologic disease].
Korsak J; Zaleska B; Orłowska E; Kotowicz J
Pol Merkur Lekarski; 2005 Jul; 19(109):98-101. PubMed ID: 16194039
[TBL] [Abstract][Full Text] [Related]
20. The steroid-sparing effect of intravenous immunoglobulin in patients with autoimmune diseases.
Zandman-Goddard G; Krauthammer A; Shoenfeld Y
Expert Rev Clin Immunol; 2007 Sep; 3(5):773-80. PubMed ID: 20477027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
